Target intelligence / Profile preview

Enthesis

Molecular classification
Other
01

Overview

The enthesis is a specialized structural interface where tendon, ligament, or joint capsule attaches into bone, transmitting and dissipating mechanical forces across dissimilar tissues. It consists of several distinct histological zones: dense fibrous collagen, uncalcified fibrocartilage, calcified fibrocartilage, and bone. Its extracellular matrix is primarily collagenous, with unique gradients and molecular specialization to facilitate stress transfer and maintain joint integrity[1][2][4][8]. Damage to the enthesis is clinically relevant in orthopedic injury, chronic inflammation (enthesitis), and repair biology. It is not a molecular drug target but rather a complex tissue relevant in tissue engineering and regenerative medicine. Note: - The enthesis is a tissue, not a canonical druggable target. - For studies interested in drugs or molecular targets at the enthesis (such as pathways involved in enthesopathy or enthesis repair), focus may be placed on signaling molecules or cells (e.g., Hedgehog pathway, chondrocytes, progenitor cells), but these are not "enthesis" itself[4][5]. - Most relevant interventions are physical (surgical reconstruction) or leverage regenerative/tissue engineering approaches. Drugs affecting enthesis pathology do so indirectly.

Other names
Tendon-bone insertionLigament-bone insertionFibrocartilaginous interface
02

Biological functions

Force transmissionLoad dispersal between tendon/ligament and boneStress adaptationBiomechanical buffering
03

Disease associations

Enthesopathy (inflammation or pathology at the enthesis)Tendon/ligament injury and repairOrthopedic diseaseEnthesitis (frequent in spondyloarthritis)
04

Safety considerations

High failure rates in surgical repair/reconstructiondifficulty in recreating natural tissue gradientspoor integration post-injury or surgerybiomechanical mismatch
05

Biomarkers

Potential research-level gene/protein expression markers (e.g., Scx, Sox9, Tnmd, Col12a1, Aggrecan, Versican, Biglycan) identified in the context of tissue engineering, repair, or transcriptomic studiesNo established clinical biomarkers for patient selection or direct monitoring

Beyond the preview

Go deeper on Enthesis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enthesis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call